Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.24, Iss.9, 2003-09, pp. : 441-443

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lithium Pharmacodynamics and Pharmacogenetics: Focus on Inositol Mono Phosphatase (IMPase), Inositol Poliphosphatase (IPPase) and Glycogen Sinthase Kinase 3 Beta (GSK-3 Beta)

Current Medicinal Chemistry, Vol. 16, Iss. 15, 2009-05 ,pp. : 1917-1948

Bentham Science Publishers

Access to resources Recommend Favorite

GSK3 Inhibitors and Disease

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 9, 2009-08 ,pp. : 1024-1029

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 965-970

Informa Healthcare

Access to resources Recommend Favorite

Inhibitory Effect of Selective Cyclooxygenase-2 Inhibitor Etoricoxib on Human Organic Anion Transporter 3 (hOAT3)

Drug Metabolism Letters, Vol. 5, Iss. 2, 2011-04 ,pp. : 137-140

Bentham Science Publishers

Access to resources Recommend Favorite

GSK-3 and the neurodevelopmental hypothesis of schizophrenia

By Kozlovsky N. Belmaker R.H. Agam G.

European Neuropsychopharmacology, Vol. 12, Iss. 1, 2002-02 ,pp. : 13-25

Elsevier

Access to resources Recommend Favorite